WASHINGTON (dpa-AFX) - Watson Pharmaceuticals, Inc. (WPI) confirmed Tuesday that the United States District Court for the District of Delaware has ruled that the asserted claims of United States Patent Nos. 7,410,978, 7,759,359), 7,781,448, 7,781,449 and 7,763,635 for Sanctura XR are invalid.
Watson's Abbreviated New Drug Application for a generic version of Sanctura XR is pending with the Food and Drug Administration.
Sanctura XR, or trospium chloride extended-release capsules, is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency.
For the twelve months ending February 29, 2012, Sanctura XR had total U.S. sales of about $68 million, according to IMS Health data.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de